Articles

Highlights in genitourinary cancer

BJMO - volume 16, issue 5, september 2022

T. Vermassen PhD, A. Decruyenaere MD, S. Rottey MD, PhD, D. De Maeseneer MD

SUMMARY

The 2022 ASCO Annual Meeting again offered a variety of advancements in the treatment of genitourinary cancers. In this summary, some of the highlights in the field of renal, bladder and prostate cancer will be discussed, with a particular focus on studies with a potential impact on clinical practice.

(Belg J Med Oncol 2022;16(5):214–22)

Read more

Highlights in genitourinary cancers

BJMO - volume 15, issue 8, december 2021

T. Vermassen PhD, S. Rottey MD, PhD, D. De Maeseneer MD

ESMO 2021 again provided a variety of innovations in the management of genitourinary cancers. In prostate cancer (PCa), results of STAMPEDE suggest that early intensification of adjuvant therapy with ADT and abiraterone could become a new standard in high-risk non-metastatic PCa (currently off-label). Studies in metastatic castration-resistant PCa (mCRPC) indicated promising activity of 77Lu-PSMA-617 plus pembrolizumab and of cabozantinib plus atezolizumab. In the field of kidney cancer, patient-reported outcome data of KEYNOTE-564 further support adjuvant pembrolizumab as a new standard of care. Other studies in renal cell cancer (RCC) showed that treatment breaks during tyrosine kinase inhibitor therapy may be highly cost-effective without an effect on patient survival, that antibiotics can severely compromise survival outcomes in nivolumab-treated metastatic RCC patients and that therapeutic targeting of HIF-2α and VEGF may be effective in patients with metastatic clear cell RCC. In addition, cabozantinib proved to be safe and effective in patients with metastatic collecting ducts carcinoma. In urothelial cancer, dose-dense MVAC was identified as a safe and effective neoadjuvant treatment option for patients with muscle-invasive bladder cancer (MIBC). In metastatic urothelial cancer the addition of cetrelimab to erdafitinib seemed to increase treatment effects, while the EphrinB2-blocking agent sEphB4-HAS was found to have synergistic activity with pembrolizumab. Finally, an exploratory analysis of the pivotal IMvigor 130 trial found that cisplatin but not carboplatin seems to enhance anti-tumour immunity.

(BELG J MED ONCOL 2021;15(8):398–405)

Read more

Highlights in genitourinary cancers

BJMO - volume 15, issue 5, september 2021

T. Vermassen PhD, S. Rottey MD, PhD, D. De Maeseneer MD

The 2021 ASCO Annual Meeting offered a variety of advancements in the treatment and detection of genitourinary cancers. For prostate cancer (PCa), matched tumour-normal tissue sequencing was shown to be the ideal standard of care (SOC) in de novo high-risk PCa patients. The addition of immune checkpoint inhibitors (ICI) to the SOC was found to be highly effective in muscle-invasive bladder cancer, with enfor-tumab vedotin (EV) continuing to show efficacy in urothelial carcinoma in a post-ICI advanced/ metastatic setting. Finally, the combination of ICI and tyrosine kinase inhibitors (TKIs) as first-line therapy for both non-clear cell and clear cell renal cell carcinoma (non-cc/ccRCC) displays a clear survival benefit, with this efficacy extending into the second-line treatment of patients with metastatic non-ccRCC who have previously received ICIs. The most important headline presentations relating to genitourinary cancers will be discussed in this congress highlights article.

(BELG J MED ONCOL 2021;15(5):256-63)

Read more

Highlights in genitourinary cancers

BJMO - volume 14, issue 8, december 2020

T. Vermassen PhD, S. Rottey MD, PhD, D. De Maeseneer MD

Over the past years, many interesting studies in the field of prostate, urothelial and renal cell carcinoma have been initiated. In this overview, practice changing data from the latest virtual ESMO meeting are presented.

Read more

An update on the management of metastatic clear-cell renal cell carcinoma: the BSMO expert panel recommendations

BJMO - volume 14, issue 2, march 2020

B. Delafontaine MD, C. De Backer MD, B. Beuselinck MD, PhD, P. Debruyne MD, PhD, L. D’Hondt MD, PhD, C. Gennigens MD, PhD, T. Gil MD, C. Vulsteke MD, N. Martínez Chanzá MD, A. Verbiest MD, M. Strijbos MD, PhD, G. Van Lancker MD, G. Pelgrims MD, S. Rottey MD, PhD, On behalf of the BSMO Uro-Oncology Task Force Group

SUMMARY

The management of recurrent or metastatic renal cell carcinoma is evolving fast, with new therapeutic options becoming available that may improve the outcome of patients. In this paper, recent evolutions are discussed and recommendations are made regarding the management of renal cell carcinoma in a Belgian context.

(BELG J MED ONCOL 2020;14(2):56–70)

Read more

Immuno-oncology combinations: rationale and clinical implications in melanoma, renal cell carcinoma and lung cancer

BJMO - volume 13, issue 9, february 2019

A. Migeotte , J-F. Baurain MD, PhD, S. Rottey MD, PhD, J. Blokken PhD, PharmD, Tom Feys MBA, MSc

ABSTRACT

Over the past years, immune checkpoint inhibitors have been widely used for the treatment of a broad range of malignancies. Unfortunately, only a proportion of patients derives long-term benefit from these therapeutics. In fact, a majority of patients fails to respond to immune checkpoint inhibition, while others relapse after a certain time. In an attempt to increase the response rate of tumours to these drugs, investigators have looked into the potential of combining different immunotherapeutic agents. Since inhibitors of the immune checkpoints CTLA-4 and PD-(L)1 have different modes of action and given the fact that blocking one of both pathways results in an upregulation of the other, provide a theoretical rationale to combine these agents. This review provides an overview of clinical studies evaluating combinations of CTLA-4 and PD-(L)1 inhibitors in the treatment of melanoma, renal cell carcinoma and non-small-cell lung cancer.

Read more

Highlights in urologic cancer

BJMO - volume 13, issue 8, december 2019

D. De Maeseneer MD, E. Werbrouck MD, S. De Keukeleire MSc, S. Rottey MD, PhD

In recent years, innovations in renal, bladder and prostate cancer treatments have been introduced at a rapid pace. Every year, oncological societies had to update treatment guidelines according to new insights and results of large phase III trials. This article focuses on practice changing data from the 2019 ESMO congress in Barcelona, Spain.

Read more
X